Physician profile
Michael Hasselle
NPI 1770741928
$393.62
in general payments reported to CMS, 2019-2025
11 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.68 · 2021: $67.55 · 2022: $145 · 2023: $17.50 · 2024: $35.53 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $126.56 | 2022 | |
| Myovant Sciences INC. | $63.68 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $47.94 | 2020-2025 | Imfinzi |
| Regeneron Healthcare Solutions, INC. | $29.09 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $28.34 | 2025 | |
| Boston Scientific Corporation | $22.29 | 2021 | |
| Ge Healthcare | $21.43 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.29 | 2025 | |
| Blue Earth Diagnostics | $17.50 | 2023 | |
| Teleflex LLC | $16.50 | 2025 | Barrigel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hasselle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.